Teri Loxam Sells 6,250 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the sale, the director now owns 7,175 shares in the company, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Vaxcyte Trading Down 2.9 %

Shares of PCVX opened at $85.30 on Monday. The firm has a 50-day moving average price of $88.08 and a 200 day moving average price of $93.67. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06. The firm has a market capitalization of $10.63 billion, a P/E ratio of -18.54 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same quarter last year, the company posted ($0.91) EPS. Equities research analysts predict that Vaxcyte, Inc. will post -4.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $140.00 target price on shares of Vaxcyte in a research report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Wednesday, November 6th. Finally, The Goldman Sachs Group began coverage on shares of Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price target on the stock. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Vaxcyte currently has a consensus rating of “Buy” and an average target price of $145.71.

Institutional Trading of Vaxcyte

Several hedge funds have recently modified their holdings of PCVX. Avior Wealth Management LLC increased its holdings in Vaxcyte by 21.1% in the fourth quarter. Avior Wealth Management LLC now owns 6,456 shares of the company’s stock valued at $528,000 after buying an additional 1,124 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Vaxcyte by 21.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,684 shares of the company’s stock valued at $220,000 after acquiring an additional 475 shares during the last quarter. Harbor Capital Advisors Inc. raised its position in shares of Vaxcyte by 15.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 74,907 shares of the company’s stock worth $6,132,000 after acquiring an additional 10,243 shares in the last quarter. Diversified Trust Co purchased a new stake in Vaxcyte during the fourth quarter worth approximately $1,433,000. Finally, Everence Capital Management Inc. acquired a new position in Vaxcyte in the fourth quarter valued at approximately $301,000. 96.78% of the stock is currently owned by institutional investors and hedge funds.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.